Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Mithra Pharmaceuticals Sa (MITRA)

Brussels
Symbol
Exchange
Currency
MITRABrusselsEUR
1TMFrankfurtEUR
Currency in EUR
Disclaimer
0.22
-0.01(-3.86%)
Closed

MITRA Comments

Mithra get ready to go above 4€ in no time , the falsh will begin now
Who will takeover mitra?
indien geen overnemer zal het game over zijn
Mithra got breakthrough wow
Mithra is going to be bankrupt?
I can't believe analysts are still giving a 12 month price target of 5.42, this sector is always with great (investor) risks
a lot of potential for the Future
Mega deal to come with catalent (CTLT) ?
The US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) *******hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
NEXSTELLIS® oral contraceptive now available in Australia26 July 2022, 07:30 CEST Adelaide, Australia and Liege, Belgium - Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce NEXSTELLIS ® (14.2 mg of estetrol and 3 mg drospirenone tablets), the first-of-its-kind oral contraceptive with a novel estrogen, is now available in Australia. NEXTSTELLIS® unlocks a new era in contraception offering women and their healthcare providers a next generation birth control pill. Every woman’s body responds differently to contraceptive hormones and having a new estrogen available – E4 – opens up the possibility that more women will be able to find a combination that suits them. Mithra is excited to see the commercialisation of NEXTSTELLIS® contraceptive on a third continent. Leon Van Rompay, CEO Mithra Women’s Health
LDA Capital commits an amount of up to EUR 75 million in cash within a maximum of five years in exchange for new ordinary shares in Mithra. This is the fourth put option notice related to this agreement, leaving EUR 54 million available to Mithra.
1 month later and 8.16, where's the bottom?
11.70, curious how low this can go. price now certainly does not represent future profits
14.00? Time to accumulate for a near future
Approval in EU is a fact. next US!
Approval US is also a fact !
Approval for Canada is now a fact!
First we need approval of Estelle & Myring in USA - 2021. 1st results are promising but still need to wait the approval. If it's a GO than Mithra will go up !!
Expectations for 2021? (with Estella going USA)
Pray wait and see 🙏🤔
With a 200 SMA (26,29) and 50 SMA (25,48) is this current 22,40 a great opportunity with a target price of 33,50
Whaha with the news of today, they still say strong sell here on Investing.com, what a joke! . Let's rise like an arrow today ;)
Added at 35,95
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.